Table 8.

FDA Labeling of Pharmacogenetic Interactions Involving Cardiovascular Drugs83

DrugPharmacogenePhenotype
CarvedilolCYP2D6CYP2D6 poor metabolizers/ultrarapid metabolizers
Clopidogrel
CYP2C19
CYP2C19 intermediate or poor metabolizers
FlecainideCYP2D6CYP2D6 poor metabolizers/ultrarapid metabolizers
Isosorbide and HydralazineNAT1-2Slow acetylators
Metoprolol
CYP2D6
CYP2D6 poor metabolizers/ultrarapid metabolizers
MexiletineCYP2D6CYP2D6 poor metabolizers/ultrarapid metabolizers
PrasugrelCYP2C19CYP2C19 poor metabolizers
CYP2C9CYP2C9 variant carriers
CYP3A5CYP3A5 variant carriers
CYP2B6CYP2B6 variant carriers
PropafenoneCYP2D6CYP2D6 poor metabolizers/ultrarapid metabolizers
PropranololCYP2D6CYP2D6 poor metabolizers/ultrarapid metabolizers
QuinidineCYP2D6CYP2D6 poor metabolizers/ultrarapid metabolizers
TicagrelorCYP2C19CYP2C19 poor metabolizers
WarfarinCYP2C9CYP2C9 intermediate or poor metabolizers
VKORC1VKORC1 A allele carriers
PROSProtein S deficient
PROCProtein C deficient